{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:47:59Z","timestamp":1791110879434,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ejso.2021.08.027","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T16:10:31Z","timestamp":1630167031000},"page":"183-187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The impact of postoperative complications following cytoreductive surgery combined with oxaliplatin based heated intraperitoneal chemotherapy"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2643-3560","authenticated-orcid":false,"given":"Victor Jilbert","family":"Verwaal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas Amstrup","family":"Funder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3106-255X","authenticated-orcid":false,"given":"Mette M\u00f8ller","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2336-2923","authenticated-orcid":false,"given":"Lene Hjerrild","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"41","key":"10.1016\/j.ejso.2021.08.027_bib1","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005111","article-title":"Short-term outcome in patients treated with cytoreduction and HIPEC compared to conventional colon cancer surgery","volume":"95","author":"Simkens","year":"2016","journal-title":"Medicine (Baltim)"},{"issue":"2","key":"10.1016\/j.ejso.2021.08.027_bib2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ejso.2005.08.009","article-title":"Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei--a report of 103 procedures","volume":"32","author":"Smeenk","year":"2006","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2021.08.027_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/jso.20013","article-title":"Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy","volume":"85","author":"Verwaal","year":"2004","journal-title":"J\u00a0Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2021.08.027_bib4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s13193-016-0504-6","article-title":"Complications of cytoreductive surgery and HIPEC in the treatment of peritoneal metastases","volume":"7","author":"Mehta","year":"2016","journal-title":"Indian J Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2021.08.027_bib5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/02656736.2017.1345014","article-title":"Teo MCC: platinum agents and mitomycin C-specific complications in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"34","author":"Tan","year":"2018","journal-title":"Int J Hyperther"},{"issue":"1","key":"10.1016\/j.ejso.2021.08.027_bib6","first-page":"99","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality","volume":"7","author":"Newton","year":"2016","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2021.08.027_bib7","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/jso.23546","article-title":"The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study","volume":"109","author":"Hompes","year":"2014","journal-title":"J\u00a0Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2021.08.027_bib8","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1245\/s10434-016-5143-1","article-title":"Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with oxaliplatin increases the risk of postoperative hemorrhagic complications: analysis of predictive factors","volume":"23","author":"Charrier","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2021.08.027_bib9","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ejso.2012.07.120","article-title":"Effect of perfusion temperature on glucose and electrolyte transport during hyperthermic intraperitoneal chemoperfusion (HIPEC) with oxaliplatin","volume":"39","author":"Ceelen","year":"2013","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2021.08.027_bib10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1245\/s10434-010-1210-1","article-title":"Severe electrolyte disturbances after hyperthermic intraperitoneal chemotherapy: oxaliplatin versus mitomycin C","volume":"18","author":"Rueth","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2021.08.027_bib11","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/DCR.0000000000000149","article-title":"Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients","volume":"57","author":"Baratti","year":"2014","journal-title":"Dis Colon Rectum"},{"issue":"8","key":"10.1016\/j.ejso.2021.08.027_bib12","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1245\/s10434-014-4297-y","article-title":"Serious postoperative complications affect early recurrence after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis","volume":"22","author":"Simkens","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"10.1016\/j.ejso.2021.08.027_bib13","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1245\/s10434-013-3145-9","article-title":"Cytoreduction and HIPEC in The Netherlands: nationwide long-term outcome following the Dutch protocol","volume":"20","author":"Kuijpers","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2021.08.027_bib14","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/jso.23228","article-title":"Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis","volume":"107","author":"Glockzin","year":"2013","journal-title":"J\u00a0Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2021.08.027_bib15","first-page":"122","article-title":"Impact of surgical volume of centers on post-operative outcomes from cytoreductive surgery and hyperthermic intra-peritoneal chemoperfusion","volume":"7","author":"Rajeev","year":"2016","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2021.08.027_bib16","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1245\/s10434-017-5821-7","article-title":"Major postoperative complications are a risk factor for impaired survival after CRS\/HIPEC","volume":"24","author":"Schneider","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"10.1016\/j.ejso.2021.08.027_bib17","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1245\/s10434-018-6823-9","article-title":"Postoperative complications independently predict cancer-related survival in peritoneal malignancies","volume":"25","author":"Choudry","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2021.08.027_bib18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1245\/s10434-018-6992-6","article-title":"Morbidity and mortality following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: data from the DGAV StuDoQ registry with 2149 consecutive patients","volume":"26","author":"Piso","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ejso.2021.08.027_bib19","first-page":"S80","article-title":"Cytoreductive surgery and HIPEC for peritoneal carcinomatosis. A review on morbidity and mortality","volume":"20","author":"Halkia","year":"2015","journal-title":"J\u00a0BUON"},{"issue":"5","key":"10.1016\/j.ejso.2021.08.027_bib20","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.ejso.2015.01.016","article-title":"Clinical features of pulmonary emboli in patients following cytoreductive surgery (peritonectomy) and hyperthermic intraperitoneal chemotherapy (hipec), a single centre experience","volume":"41","author":"Vukadinovic","year":"2015","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2021.08.027_bib21","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/jso.25437","article-title":"Body surface area-based vs concentration-based perioperative intraperitoneal chemotherapy after optimal cytoreductive surgery in colorectal peritoneal surface malignancy treatment: COBOX trial","volume":"119","author":"Lemoine","year":"2019","journal-title":"J\u00a0Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2021.08.027_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00001813-200501000-00006","article-title":"Phase I dose escalation study of oxaliplatin combined with oral tegafur-uracil and leucovorin in patients with advanced gastric cancer","volume":"16","author":"Chen","year":"2005","journal-title":"Anti Canc Drugs"},{"issue":"5","key":"10.1016\/j.ejso.2021.08.027_bib23","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/jso.25438","article-title":"Cytoreduction and hyperthermic intraperitoneal chemotherapy in metastatic colorectal cancer","volume":"119","author":"Eng","year":"2019","journal-title":"J\u00a0Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2021.08.027_bib24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/SLA.0b013e3181c9b53c","article-title":"Evaluation of the cost-effectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (peritonectomy) at the St George Hospital peritoneal surface malignancy program","volume":"251","author":"Chua","year":"2010","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.ejso.2021.08.027_bib25","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/jso.24162","article-title":"Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a community setting: a cost-utility analysis of a hospital's initial experience and reflections on the health care system","volume":"113","author":"Naffouje","year":"2016","journal-title":"J\u00a0Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2021.08.027_bib26","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/jso.23722","article-title":"American Society of Peritoneal Surface Malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer","volume":"110","author":"Esquivel","year":"2014","journal-title":"J\u00a0Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2021.08.027_bib27","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.soc.2018.02.009","article-title":"Learning curve, training program, and monitorization of surgical performance of peritoneal surface malignancies centers","volume":"27","author":"Kusamura","year":"2018","journal-title":"Surg Oncol Clin"},{"issue":"11","key":"10.1016\/j.ejso.2021.08.027_bib28","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/bjs.5863","article-title":"Learning curve of combined modality treatment in peritoneal surface disease","volume":"94","author":"Smeenk","year":"2007","journal-title":"Br J Surg"},{"issue":"2","key":"10.1016\/j.ejso.2021.08.027_bib29","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ejso.2015.08.162","article-title":"Cytoreduction and hyperthermic intraperitoneal chemotherapy: the learning curve reassessed","volume":"42","author":"Kuijpers","year":"2016","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2021.08.027_bib30","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1111\/codi.12185","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience","volume":"15","author":"Iversen","year":"2013","journal-title":"Colorectal Dis"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798321006995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798321006995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:40:09Z","timestamp":1760060409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798321006995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0748798321006995"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2021.08.027","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of postoperative complications following cytoreductive surgery combined with oxaliplatin based heated intraperitoneal chemotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2021.08.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}